Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DarioHealth Corp.DRIO · Entity 7024 | Director | June 06, 2018 | June 08, 2018 |
| Fortress Biotech, Inc.FBIO · Entity 6822 | Director | January 01, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DarioHealth Corp.
Report date June 06, 2018 · Filed June 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,033 |
Reported balance
After 2018-06-06 transaction · row 1
1 source rowRow 1 · 2018-06-06 · Grant · Acquired 24,353 · Balance 78,033 |
Fortress Biotech, Inc.
Report date January 01, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001SEC Table I · non-derivative | Direct | 115,747 |
Reported balance
After 2026-01-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-01 · Grant · Acquired 27,322 · Balance 115,747 F1: The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service. The Reporting Person elected to defer 25% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F2: Total holdings include 52,507 shares underlying deferred restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service. The Reporting Person elected to defer 25% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer.
F2: Total holdings include 52,507 shares underlying deferred restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2026 Filed Jan 5, 2026 21:30 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 27,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001294517-26-000002 · form4-01052026_040113.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,747 F1 · shares: The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service. The Reporting Person elected to defer 25% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F2 · balance_after: Total holdings include 52,507 shares underlying deferred restricted stock units. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:20 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 49,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000425 · form4-01032025_040101.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,425 F1 · shares: The Reporting Person was granted 49,383 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2026, 2027, and 2028, subject to continued service. The reporting person elected to defer 25% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F2 · balance_after: Total holdings include 45,676 shares underlying deferred restricted stock units. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:50 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-000905 · tm241755-5_4seq1.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,042 F1 · shares: Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. F2 · shares: One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F3 · balance_after: Total holdings include 33,330 shares underlying deferred restricted stock units. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 02:24 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001095 · tm231728-2_4seq1.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 535,636 F1 · shares: One-third of the shares will vest on each of January1, 2024, 2025 and 2026, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the Issuer. F2 · balance_after: The total holdings include 450,000 shares underlying deferred restricted stock units. Read SEC document |
| January 01, 2022 Filed Apr 29, 2022 20:22 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-053616 · tm2213913-7_4seq1.xml · nonDerivative · entry 3 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,636 F4 · shares: One-third of the shares will vest on each of January 1, 2023, 2024, and 2025, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer. F5 · balance_after: The total holdings include 400,000 shares underlying deferred restricted stock units. Read SEC document |
| November 16, 2021 Filed Apr 29, 2022 20:22 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | OtherCommon Stock | 230 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-053616 · tm2213913-7_4seq1.xml · nonDerivative · entry 2 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,636 F3 · kind: The shares were issued upon the consummation of Journey Medical Corporation ("Journey's") initial public offering as a partial dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey's 8% Cumulative Convertible Class A Preferred Stock F2 · balance_after: The total holdings include 350,000 shares underlying deferred restricted stock units. Read SEC document |
| September 30, 2021 Filed Apr 29, 2022 20:22 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | OtherCommon Stock | 406 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-053616 · tm2213913-7_4seq1.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,406 F1 · kind: The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock. F2 · balance_after: The total holdings include 350,000 shares underlying deferred restricted stock units. Read SEC document |
| January 01, 2021 Filed Apr 9, 2021 21:22 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-048824 · tm219139d2_4.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,000 F1 · shares: One-third of the shares will vest on each of January 1, 2022, 2023 and 2024, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer. F2 · balance_after: The total holdings include 350,000 shares underlying deferred restricted stock units. Read SEC document |
| August 26, 2020 Filed Sep 1, 2020 12:34 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 16,667 | $18.00 | $300,006.00 |
DisclosureSEC source: 0001104659-20-101102 · tm2029961-2_4.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Read SEC document |
| January 01, 2020 Filed Mar 13, 2020 20:06 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-033109 · tm2011481-2_form4.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,000 F1 · shares: One-third of the shares will vest on each January 1, 2021, 2022 and 2023, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer. F2 · balance_after: The total holdings include 250,000 shares underlying deferred restricted stock units. Read SEC document |
| January 01, 2019 Filed Apr 12, 2019 20:09 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-019495 · tv516218_4.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,000 F1 · shares: One-third of the shares will vest on each January 1, 2020, 2021 and 2022, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer. F2 · balance_after: The total holdings include 250,000 shares underlying deferred restricted stock units. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 16:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 24,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-033546 · tv496163_4.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,033 Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 16:12 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 6,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-022385 · tv491869_4.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,680 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the first quarter of 2018 in the amount of $10,250. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 16:18 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 6,531 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-001312 · tv482701_4.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,027 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the fourth quarter of 2017 in the amount of $10,250. Read SEC document |
| January 01, 2018 Filed Nov 30, 2018 22:30 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-062682 · tv495938_4.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,000 F1 · shares: One-third of the shares will vest on each January 1, 2019, 2020 and 2021, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer. F2 · balance_after: The total holdings include 50,000 shares underlying deferred share units that were previously reported in Table II. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 16:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 5,521 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-054097 · tv477609_4.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,496 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the third quarter of 2017 in the amount of $10,250. Read SEC document |
| July 10, 2017 Filed Jul 11, 2017 16:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 4,433 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-036438 · v470578_4.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,975 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the second quarter of 2017 in the amount of $10,250. Read SEC document |
| April 13, 2017 Filed Apr 17, 2017 16:25 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 2,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-020721 · v464370_4.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,542 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the first quarter of 2017 in the amount of $10,250. Read SEC document |
| March 10, 2017 Filed Jul 21, 2017 20:11 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantDeferred Restricted Stock Units · Derivative | 16,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000720 · doc4_4609.xml · derivative · entry 2 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,998 Underlying: Common Stock · 16,666 shares Expires not disclosed F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs") for service as a director in 2015, vesting one-third annually beginning on March 12, 2016. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. F2 · price: Upon the vesting of RSUs, the Reporting Person deferred the receipt of 16,666 shares of common stock and received instead 16,666 shares of deferred RSUs. Page F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") for service as a director in 2015, vesting one-third annually beginning on March 12, 2016. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs") for service as a director in 2015, vesting one-third annually beginning on March 12, 2016. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 16:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantStock Option (right to buy) · Derivative | 16,007 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001144204-17-005356 · v457882_4.xml · derivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,007 Underlying: Common Stock · 16,007 shares Expires 2023-01-30 F1 · derivative.exercise_date: The option vests in twelve equal quarterly installments commencing on January 30, 2017. Read SEC document |
| January 12, 2017 Filed Jan 13, 2017 16:46 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 6,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-002219 · v456903_4.xml · nonDerivative · entry 1 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,742 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the third quarter and fourth quarter of 2016 in the amount of $20,500. Read SEC document |
| January 01, 2017 Filed Jan 24, 2017 23:56 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantDeferred Restricted Stock Units · Derivative | 16,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000106 · doc4_4430.xml · derivative · entry 2 Hoenlein Malcolm · CIK 0001294517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,332 Underlying: Common Stock · 16,666 shares Expires not disclosed F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs") for service as a director in 2016, vesting one-third annually beginning on January 1, 2017. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. F2 · price: Upon the vesting of RSUs, the Reporting Person deferred the receipt of 16,666 shares of common stock and received instead 16,666 shares of deferred RSUs. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") for service as a director in 2016, vesting one-third annually beginning on January 1, 2017. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs") for service as a director in 2016, vesting one-third annually beginning on January 1, 2017. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.